OncoMatch/Clinical Trials/NCT03737955
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Is NCT03737955 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Gemtuzumab Ozogamicin for acute myeloid leukemia.
Treatment: Gemtuzumab Ozogamicin — This phase II trial studies the how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in patients with acute myeloid leukemia. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to a chemotherapy drug, called ozogamicin. Gemtuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD33 receptors, and delivers a chemotherapy known as calicheamicin to kill them.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: CD33 expression
Patient's AML blasts must have CD33 expression.
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: cytotoxic chemotherapy — induction
Patients must have received at least 1 cycle of standard induction chemotherapy prior to enrollment on the study.
Cannot have received: chemotherapy
Exception: within 14 days prior to entering the study
Subjects who have had chemotherapy or radiation therapy within 14 days prior to entering the study.
Cannot have received: radiation therapy
Exception: within 14 days prior to entering the study
Subjects who have had chemotherapy or radiation therapy within 14 days prior to entering the study.
Cannot have received: investigational agent
Subjects may not be receiving other investigational agents.
Lab requirements
Kidney function
Serum creatinine <= 2.0 mg/dL
Liver function
Total bilirubin <= 2 x institutional upper limit of normal for age (unless known history of Gilbert's disease); AST and ALT < 2.5 x institutional upper limit of normal for age (unless thought to be related to resolving infectious complications)
Serum creatinine <= 2.0 mg/dL. Total bilirubin <= 2 x institutional upper limit of normal for age (unless known history of Gilbert's disease). AST and ALT < 2.5 x institutional upper limit of normal for age (unless thought to be related to resolving infectious complications).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fred Hutchinson Cancer Center/University of Washington Cancer Consortium · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify